trending Market Intelligence /marketintelligence/en/news-insights/trending/JYx4SAndtRU4k4Rd_cxzSQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Curis to sell royalty portion from cancer drug to Oberland for up to $135.7M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Curis to sell royalty portion from cancer drug to Oberland for up to $135.7M

Lexington, Mass.-based Curis Inc. agreed to sell the rights to a portion of royalties from skin cancer drug Erivedge to Oberland Capital Management LLC for up to $135.7 million.

Under the deal, Curis received $65 million upfront and is expected to receive up to an additional $70.7 million in milestone payments if future royalties exceed certain targets.

In exchange, New York-based Oberland Capital will receive the entire $13.2 million from the first annual royalties due to Curis followed by a 35% portion thereafter. This would exclude a portion of non-U.S. royalties that will be retained by Curis.

Curis said it used certain proceeds from the transaction to retire existing debt, with remaining funds of about $30 million to be used to support its operations.

Erivedge, which is being commercialized by Roche Holding AG, is approved to treat advanced basal cell carcinoma. The disease begins in the basal cells — a type of cell within the skin that produces new skin cells as old ones die off.